Tarlatamab (Imdelltra)

Canada’s Drug Agency (CDA-AMC) recommends that Imdelltra be reimbursed by public drug plans for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy if certain conditions are met. Imdelltra should only be covered to treat adult patients who have relapsed or refractory small cell lung cancer (SCLC), have received 2 or more lines of previous therapies (including 1 chemotherapy containing platinum and at least 1 other therapy), and who are in relatively good health. Imdelltra should not be covered for patients with untreated or symptomatic brain metastases. Imdelltra should only be reimbursed if administered in centres with appropriate medical support to manage potentially life-threatening adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and if the cost of Imdelltra is reduced.